Form 4 Hims & Hers Health, Inc. For: May 20 Filed by: Boughton Soleil
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall St set to climb as US, Iran halt attacks; Comcast surges on spin-off plan
- Tech funds suffer record outflows as investors trim equity positions
- Comcast to split cable business from media in NBCUniversal, Sky spinoff
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- Micron ships 245TB data center SSD, claims world's highest capacity
- Triller to acquire SpaceX exposure as treasury asset via fund structure
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
Hims and Hers (HIMS) PT Raised to $24 at Canaccord Genuity
May 22, 2024 5:29 AM EDTCanaccord Genuity analyst Maria Ripps raised the price target on Hims and Hers (NYSE: HIMS) to $24.00 (from $20.00) while maintaining a Buy rating.
The analyst comments "On Monday, 5/20, Hims & Hers announced the addition of GLP-1 treatment to its portfolio of weight loss solutions, with prices... More
